Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

EKR Therapeutics

Request full access

ekrtx.com - Deze website is te koop! - de beste bron van informatie over ekrtx.

Bedminster Township, United StatesFounded 2006Biotechnology

About EKR Therapeutics

EKR Therapeutics, Inc. was a specialty pharmaceutical company concentrating on the acute-care hospital market. Founded in late 2005 by Howard Weisman, S. Douglas Sheldon, and Dr. Jeffery Z. Li, the company focused on acquiring, developing, and commercializing products for critical care. Howard Weisman, who served as Chairman and CEO, brought significant industry experience to the firm, having previously co-founded ESP Pharma and held various roles at Merck and Pfizer. This background in cardio-neurovascular products and specialty pharmaceuticals shaped EKR's strategy of addressing unmet needs in hospital settings.

The company's business model revolved around acquiring and marketing proprietary products directly to hospitals, with a focus on areas like cardiovascular health, pain management, and oncology supportive care. EKR's revenue was generated through the sales of its product portfolio, which it built through a series of acquisitions. This strategy was designed to create a commercially focused organization that could enhance the therapeutic value of acute-care treatments.

EKR's product lineup included Cardene I.V. (nicardipine hydrochloride), an intravenous treatment for short-term hypertension, and Retavase, a drug for managing acute myocardial infarction (AMI). In 2008, the company received FDA approval for a ready-to-use premixed intravenous bag for Cardene I.V., simplifying its administration in critical care settings. The portfolio also featured DepoDur, an extended-release morphine for post-operative pain, and Gelclair, a bioadherent oral gel to manage pain from oral mucositis, often a side effect of cancer treatments. In 2011, sales were primarily driven by Cardene I.V., generating $58 million in net revenue.

A significant milestone in the company's history was its acquisition by Cornerstone Therapeutics Inc. in June 2012. The deal was valued at up to $150 million, consisting of a $125 million initial cash payment and up to $25 million in potential milestone payments tied to Retavase sales. This acquisition expanded Cornerstone's footprint in the hospital therapeutics market, integrating EKR's cardiovascular products and sales infrastructure into its operations, at which point EKR became a wholly owned subsidiary. The company had previously secured substantial funding from venture capital and private equity firms, including a $50 million Series D round in 2008, to finance its product acquisition strategy.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
20
Open positions
None listed
Dealroom signal
20.3/100
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit May 2012 $150M $150M Cornerstone Therapeutics —
DEBTDebt Mar 2008 $95M — Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

EKR Therapeutics website traffic

Latest recorded traffic for EKR Therapeutics is 250 monthly website visits. EKR Therapeutics's team declined 23.1% over the past year.

Latest monthly visits250 1-year team growth-23.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

EKR Therapeutics in the Bedminster Township ecosystem

Live from Dealroom

The EKR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • NewSpring Ventures
  • ESP Equity Partners

Series B and later3 investors entered at this stage

  • Quaker Bio Ventures
  • Merrill Lynch
  • NewSpring Capital

Other known investors1 additional known investor

  • Cornerstone Therapeutics
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about EKR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EKR Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.